A clinical trial of active immunotherapy with anti-idiotypic vaccine in nasopharyngeal carinoma patients

摘要

Conclusions Anti-idiotype vaccine is safe for clinical active immunotherapy. Anti-idiotypic vaccine might be able to enhance humoral and/or cellular immunity in NPC patients receiving radiotherapy. Objective To investigate the effect of active immunotherapy with anti-idiotypic vaccine in patients with Nasopharyngeal carcinoma(NPC). Methods Anti-idiotypic antibodies(2H4/5D3)bearing the internal image of the NPC antigen were used in Active immunotherapy in NPC patients receiving radiotherapy. Antibodies and cytokine levels in patients sera Were determined using ELISA before and after active immunotherapy.